Tolvaptan for the treatment of heart failure: A review of the literature

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 6, 2011, Pages 961-976

  Ambrosy, Andrew ^a   Goldsmith, Steven R ^b   Gheorghiade, Mihai ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute heart failure syndromes; antidiuretic hormone; arginine vasopressin; heart failure; tolvaptan

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGIPRESSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; LOOP DIURETIC AGENT; PLACEBO; TOLVAPTAN; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V2 RECEPTOR; WARFARIN;

ACUTE HEART FAILURE; ARTICLE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DIURESIS; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ELECTROLYTE DISTURBANCE; FATIGUE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FILLING PRESSURE; HEART LEFT VENTRICLE REMODELING; HOSPITAL READMISSION; HUMAN; HYPERNATREMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; MAXIMUM PLASMA CONCENTRATION; MORTALITY; NONHUMAN; POLYDIPSIA; POLYURIA; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SERUM OSMOLALITY; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; THIRST; URINE VOLUME; WATER RETENTION; WEIGHT CHANGE; WEIGHT REDUCTION; XEROSTOMIA;

ANIMALS; BENZAZEPINES; CLINICAL TRIALS AS TOPIC; CONSENSUS; DISEASE MODELS, ANIMAL; DIURESIS; DIURETICS; HEART FAILURE; HUMANS; HYPONATREMIA; TOXICITY TESTS; TREATMENT OUTCOME;

EID: 79952768369     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.567267     Document Type: Article

References (74)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010;121:e46-215
2. Pang PS, Komajda M, Gheorghiade M. The current and future management of acute heart failure syndromes. Eur Heart J 2010;31:784-93
3. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006;296:2217-26 (Pubitemid 44708052)
4. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res 2001;51:372-90 (Pubitemid 32718586)
5. Lee CR, Watkins ML, Patterson JH, et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003;146:9-18 (Pubitemid 36851295)
6. Jard S. Mechanisms of action of vasopressin and vasopressin antagonists. Kidney Int Suppl 1988;26:S38-42
7. Xu YJ, Gopalakrishnan V. Vasopressin increases cytosolic free [Ca2+] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors. Circ Res 1991;69:239-45
8. Nakamura Y, Haneda T, Osaki J, et al. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. Eur J Pharmacol 2000;391:39-48 (Pubitemid 30138078)
9. Penit J, Faure M, Jard S. Vasopressin and angiotensin II receptors in rat aortic smooth muscle cells in culture. Am J Physiol 1983;244:E72-82 (Pubitemid 13195609)
10. Nielsen S, Chou CL, Marples D, et al. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci USA 1995;92:1013-17
11. Kalra PR, Anker SD, Coats AJ. Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin. Cardiovasc Res 2001;51:495-509 (Pubitemid 32718598)
12. Goldsmith SR, Francis GS, Cowley AW Jr, et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983;1:1385-90 (Pubitemid 13054124)
13. Yamane Y. Plasma ADH level in patients with chronic congestive heart failure. Jpn Circ J 1968;32:745-59
14. Szatalowicz VL, Arnold PE, Chaimovitz C, et al. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981;305:263-6 (Pubitemid 11087371)
15. Preibisz JJ, Sealey JE, Laragh JH, et al. Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 1983;5:I129-138
16. Riegger GA, Liebau G, Kochsiek K. Antidiuretic hormone in congestive heart failure. Am J Med 1982;72:49-52 (Pubitemid 12090785)
17. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9 (Pubitemid 20367975)
18. Isnard R, Pousset F, Trochu J, et al. Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. Am J Cardiol 2000;86:417-21 (Pubitemid 30628608)
19. Schiff GD, Fung S, Speroff T, McNutt RA. Decompensated heart failure: symptoms, patterns of onset, and contributing factors. Am J Med 2003;114:625-30 (Pubitemid 36703230)
20. Adamson PB, Magalski A, Braunschweig F, et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol 2003;41:565-71 (Pubitemid 36223320)
21. Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med 2006;119:S3-10
22. Gheorghiade M, De Luca L, Fonarow GC, et al. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol 2005;96:11G-7G
23. Kono T, Sabbah HN, Rosman H, et al. Left ventricular shape is the primary determinant of functional mitral regurgitation in heart failure. J Am Coll Cardiol 1992;20:1594-8 (Pubitemid 23007515)
24. Sabbah HN, Rosman H, Kono T, et al. On the mechanism of functional mitral regurgitation. Am J Cardiol 1993;72:1074-6 (Pubitemid 23319932)
25. Grossman E, Oren S, Messerli FH. Left ventricular filling and stress response pattern in essential hypertension. Am J Med 1991;91:502-6
26. Grossman W. Diastolic dysfunction and congestive heart failure. Circulation 1990;81:III1-7
27. Hasselblad V, Gattis Stough W, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007;9:1064-9 (Pubitemid 47451811)
28. Gheorghiade M, Rossi JS, Cotts W, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med 2007;167:1998-2005 (Pubitemid 47606641)
29. Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 2007;28:980-8 (Pubitemid 47343897)
30. Rossi J, Bayram M, Udelson JE, et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card Care 2007;9:82-6 (Pubitemid 46955230)
31. Klein L, O'Connor CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005;111:2454-60 (Pubitemid 40696133)
32. Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998;287:860-7 (Pubitemid 29131593)
33. Gheorghiade M, Teerlink JR, Mebazaa A. Pharmacology of new agents for acute heart failure syndromes. Am J Cardiol 2005;96:68G-73G (Pubitemid 41338076)
34. Shoaf SE, Wang Z, Bricmont P, Mallikaarjun S. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects. J Clin Pharmacol 2007;47:1498-507 (Pubitemid 350115300)
35. Shoaf SE, Elizari MV, Wang Z, et al. Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias. J Cardiovasc Pharmacol Ther 2005;10:165-71 (Pubitemid 41376974)
36. Hirano T, Yamamura Y, Nakamura S, et al. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 2000;292:288-94 (Pubitemid 30026383)
37. Miyazaki T, Yamamura Y, Onogawa T, et al. Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia. Endocrinology 2005;146:3037-43 (Pubitemid 41002811)
38. Veeraveedu PT, Watanabe K, Ma M, et al. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure. Biochem Pharmacol 2007;74:1466-75 (Pubitemid 47575494)
39. Veeraveedu PT, Watanabe K, Ma M, et al. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Biochem Pharmacol 2008;75:1322-30
40. Miyazaki T, Fujiki H, Yamamura Y, et al. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist-pharmacology and clinical trials. Cardiovasc Drug Rev 2007;25:1-13 (Pubitemid 46625287)
41. Udelson JEOC, O'Brien T, Sequeira R, et al. Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo-controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination [abstract]. J Am Coll Cardiol 2002;39:810
42. Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 2006;290:F273-278 (Pubitemid 43724981)
43. Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008;52:1540-5
44. Paterna S, Di Pasquale P, Parrinello G, et al. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study. J Am Coll Cardiol 2005;45:1997-2003 (Pubitemid 40814121)
45. Udelson JE, McGrew FA, Flores E, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 2007;49:2151-9 (Pubitemid 46817812)
46. Gheorghiade M, Gottlieb SS, Udelson JE, et al. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol 2006;97:1064-7
47. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-112 (Pubitemid 44749318)
48. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003;107:2690-6 (Pubitemid 36667242)
49. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291:1963-71 (Pubitemid 38544277)
50. Gheorghiade M, Orlandi C, Burnett JC, et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: outcome study with tolvaptan (EVEREST). J Card Fail 2005;11:260-9 (Pubitemid 40626781)
51. Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation 2005;112:3958-68 (Pubitemid 43739494)
52. Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007;297:1332-43 (Pubitemid 46513234)
53. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 2007;297:1319-31 (Pubitemid 46513233)
54. Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010;21:705-12
55. Mebazaa A, Pang PS, Tavares M, et al. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J 2010;31:832-41
56. Yancy CW. Climbing the mountain of acute decompensated heart failure: the EVEREST trials. JAMA 2007;297:1374-6 (Pubitemid 46513238)
57. Pang PS, Konstam MA, Krasa HB, et al. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J 2009;30:2233-40
58. Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 1992;86:431-8
59. Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 1995;91:2573-81
60. Doughty RN, Whalley GA, Gamble G, et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997;29:1060-6 (Pubitemid 27149582)
61. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;106:920-6 (Pubitemid 34925324)
62. Rousseau MF, Konstam MA, Benedict CR, et al. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol 1994;73:488-93
63. Tahara A, Tomura Y, Wada K, et al. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc Res 1998;38:198-205 (Pubitemid 28275630)
64. Fukuzawa J, Haneda T, Kikuchi K. Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol Cell Biochem 1999;195:93-8 (Pubitemid 29259773)
65. Walker BR, Childs ME, Adams EM. Direct cardiac effects of vasopressin: role of V1-and V2-vasopressinergic receptors. Am J Physiol 1988;255:H261-265
66. Goldsmith SR, Francis GS, Cowley AW Jr, et al. Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol 1986;8:779-83 (Pubitemid 16023631)
67. Creager MA, Faxon DP, Cutler SS, et al. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system. J Am Coll Cardiol 1986;7:758-65 (Pubitemid 16107118)
68. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005;46:1785-91 (Pubitemid 41579797)
69. Naitoh M, Suzuki H, Murakami M, et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol 1994;267:H2245-2254
70. Wang YX, Franco R, Gavras I, Gavras H. Effects of chronic administration of a vasopressin antagonist with combined antivasopressor and antiantidiuretic activities in rats with left ventricular dysfunction. J Lab Clin Med 1991;117:313-18
71. Nishikimi T, Kawano Y, Saito Y, Matsuoka H. Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats. J Cardiovasc Pharmacol 1996;27:275-82 (Pubitemid 26039450)
72. Yatsu T, Tomura Y, Tahara A, et al. Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol 1999;376:239-46 (Pubitemid 29320148)
73. Mondritzki T, Kolkhof P, Sabbah HN, et al. Differentiation of arginine vasopressin antagonistic effects by selective V2 versus dual V2/V1a receptor blockade in a preclinical heart failure model. Am J Ther 2010
74. Goldsmith SR, Elkayam U, Haught WH, et al. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail 2008;14:641-7